Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly (60 years old) patients with AML. Published literature on the topic was scant, and the review included only 22 articles examining outcomes. Twelve studies examined treatment-specific outcomes; most of these examined azacitidine or intensive chemotherapy (IC). An international randomized controlled trial found that azacitidine significantly improved overall survival relative to conventional regimens including IC and low-dose cytarabine in patients aged > 65 years. Similar results in favor of azacitidine were demonstrated in 2 other studies. IC was generally associated with longer survival versus lower-intensity therapy or best supportive care. Findings suggest that azacitidine is a viable option for elderly AML patients who are ineligible for IC, and emerging agents used in combination with azacitidine could have a major impact in this difficult-to-treat population.
Introduction

AML Background
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy 1, 2 characterized by the clonal proliferation of myeloid progenitor cells in the bone marrow, blood, and other tissues, 3 leading to the development of cytopenias. AML is the second most common type of leukemia among adults, 4 with an estimated 21,380 newly diagnosed patients in 2017 in the United States.
AML is most commonly seen in the elderly population; the median age at diagnosis is 67 years, with approximately one third of patients aged 75 years or older. 3 The Surveillance, Epidemiology, and End
Results (SEER) Program of the National Cancer Institute reports that in the United States, the incidence of AML is 4.3 per 100,000 persons 5 ; however, the reported incidence per 100,000 is much higher among elderly persons, ranging from 12.2 for those aged 65 to 69 up to 28.5 for those aged 80 to 84. 6 A similar trend is observed in Europe, where the incidence of AML among the general population is 3.7 per 100,000 and increases to 13.7 per 100,000 among those aged 65 and older. 7 AML is the leading cause of leukemia-related deaths in the United States, with 10,590 deaths in 2017. In Europe, the relative 5-year survival rate is only 5% among those aged 65 years or older. 7 Biologically, AML is associated with several genetic alterations, and karyotypic results represent the most important prognostic factor in predicting survival outcomes, relapse rates, and remission rates. 3 As such, cytogenetic analyses are the basis of risk stratification for patients with AML. 3 Patients with normal karyotype AML have a favorable risk status, whereas those with complex or monosomal karyotypes are considered to have a poor risk status. Specific 1 Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA molecular mutations have also been added to the risk stratification algorithm; certain mutations, including mutations in FLT3 and TP53, are associated with a poor prognosis. 3 The biological features of the disease shift toward a poorer risk status with increasing age.
Older patients are more likely to have high-risk cytogenetics, other hematologic disorders or secondary AML, or higher expression of genes that confer drug resistance. 3, 8, 9 Treatment Recommendations. The National Comprehensive Cancer Network (NCCN) recommends that the decision-making process for AML treatment in patients aged 60 years or older should be driven by an assessment of cytogenetic or molecular mutations, Eastern Cooperative Oncology Group (ECOG) performance status, and comorbidities, rather than age alone. 3 Treatment strategies for elderly AML patients include intensive chemotherapy (IC), low-intensity chemotherapy, and best supportive care (BSC). For newly diagnosed, elderly AML patients who have a low risk of cytogenetic or molecular abnormalities and are otherwise healthy, standard IC regimens including AraC (also known as cytarabine or cytosine arabinoside) and/or anthracycline may be beneficial, whereas patients with significant comorbidities limiting their ability to tolerate IC may benefit from induction with a lower-intensity regimen. After induction chemotherapy, AraC (standard or intermediate dose) and hypomethylating agent (HMA) regimens are generally recommended for consolidation therapy. For patients who do not respond to induction therapy, there are 2 recommendations: either BSC, or reducedintensity conditioning (RIC) preceding allogeneic hematopoietic stem-cell transplantation (HSCT) in the context of a clinical trial.
Treatment Outcomes in the Elderly. Elderly AML patients with poor-risk cytogenetics, age 80, ECOG performance status 2, multiple comorbidities, and secondary AML are more likely to experience AML relapse or disease progression after intensive induction chemotherapy. 3 Elderly patients also are more likely to have a higher incidence of comorbidities and decreased performance status at the time of diagnosis. Collectively, these disadvantages contribute to poorer prognoses and poorer tolerance to intensive therapeutic regimens when compared to younger patients. 8 Indeed, while a complete response (CR) is expected in 60% to 70% of newly diagnosed AML patients receiving first-line IC, only 40% to 50% of patients aged 65 years or older will achieve CR. 10 Longterm outcomes also are better in younger patients. The survival rate for elderly patients with AML is just 5% at 5 years after diagnosis compared to 40% in the younger population.
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Unmet Need. Despite advances in the understanding of how cytogenetics and molecular mutations affect risk stratification in AML, treatment strategies have not significantly changed since the introduction of AraC and anthracycline combination regimens several decades ago. 1 There has been minimal progress on improving the survival rates for patients with AML. 1 Given the prevalence of AML in the elderly and their limited treatment options, a significant unmet need remains for development of more effective therapies with tolerable safety profiles in this population. Therefore, the purpose of this review was to systematically collect and assess recent evidence on effectiveness and safety outcomes associated with therapeutic regimens used to treat elderly AML patients to better understand this difficult-to-treat population.
Methods
This systematic literature review (SLR) was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A prospective protocol was used to systematically search Medline (via PubMed) and Embase to identify recent studies (January 1, 2014, to May 25, 2016) , not yet covered by an existing SLR, that reported treatment outcomes in elderly patients with AML. We also reviewed conference abstracts for meetings held during the same time-period by the following groups: American Society of Clinical Oncology, American Society of Hematology, European Hematology Association, European Society for Medical Oncology, and International Society for Pharmacoeconomics and Outcomes Research.
In the first round of screening, a single investigator screened all titles and abstracts identified from the literature search against the predetermined inclusion and exclusion criteria (Table 1) . To confirm accuracy, a second investigator validated 10% of the rejected abstracts.
The full-text articles that passed abstract screening were retrieved for further review using the same inclusion criteria applied for abstract screening. All excluded studies were confirmed by a second investigator and discrepancies were resolved by a third. Elderly Patients With AML
Results
Overall Results
Twelve studies (discussed in 14 articles) examining either effectiveness or safety of a specific intervention administered to patients with AML were included in the review. Figure 1 shows the PRISMA diagram of study attrition. As the search criteria were optimized to identify real-world evidence, the majority of included publications had observational study designs (n ¼ 12). The geographic locations for the studies were Europe (n ¼ 7), the United States (n ¼ 3), Japan (n ¼ 1), and multinational (n ¼ 1).
Summary of Studies by Treatment and Patient Characteristics
In the 14 articles that evaluated elderly patients with AML, the most common treatment setting was first line (n ¼ 13). Azacitidine and IC were the most common treatment regimens examined (n ¼ 6 each). Among other comparators were AraC (low dose [LD] as monotherapy or higher dose in combination with other agents), RIC HSCT, BSC, or palliative care. Most publications reported data on cytogenetics and on the percentage of bone marrow blasts. Approximately half reported on hemoglobin levels and platelet counts. Across the articles, the mean participant age ranged from 70 to 76 years. 12 In a second noncomparative study by Delia et al, 13 median OS was 23 months in patients whose disease responded to azacitidine treatment versus 6 months in patients whose disease did not respond to therapy. Garcia-Manero et al 14 found that the 1-year OS among patients receiving azacitidine plus pracinostat was 60%; median OS was not reached in the overall population nor in the subpopulations of interest (patients with highrisk cytogenetics, AML as a result of myelodysplastic syndromes, or patients who had received prior anticancer therapy).
Outcomes
In the comparative observational studies, Caroline et al 15 found 1-year OS to be 67.8% among patients who received azacitidine versus 36.9% among those who did not; however, this difference was not sustained for the 2-year OS endpoint (25.6% and 25.9%, respectively). Michallet et al, 16 examining azacitidine versus moderateintensity chemotherapy, LD-AraC, palliative therapy, and other therapy, noted that the 2-year probability of OS was 37% for elderly patients with poor prognoses who received azacitidine and only 5% for their counterparts who received LD-AraC.
Response Rates
Response data were reported in 5 of the 6 studies. An overall response rate (ORR) of 17.0% was reported in a noncomparative study of azacitidine. 12 In the RCT, 18 ORRs of 27.8% and 25.1%
and CRs of 19.5% and 21.9% were reported for azacitidine and CCR, respectively. Caroline et al, 15 comparing CR outcomes in fit and frail patients, demonstrated a significant advantage with respect to CR for fit patients (40.3% vs. 3.8% for fit vs. frail patients, respectively). CR rates of 46% and 42% were reported. 13, 14 Safety. Three studies assessed the safety of azacitidine for AML patients aged 60 years or older. The phase 3, multicountry, RCT 18 of azacitidine versus CCR reported that the frequency of grade 3/4 treatment-emergent adverse events (AEs) is similar among patients treated with azacitidine, LD-AraC, and IC ( (Table 4) . Three of these 6 studies were conducted in France (n ¼ 3), 2 in the United States (n ¼ 2), and 1 in Japan (n ¼ 1). All studies focused on IC.
Survival
Among the 4 comparative observational studies, IC was generally associated with longer median OS than was lower-intensity therapy (LD-AraC and HMAs) or BSC; in some analyses, however, the difference was not statistically significant when the analysis was stratified by regimen subgroups. One French study 22 reported that median OS for patients receiving IC was longer than for those receiving lower-intensity therapy (LD-AraC, azacitidine, or decitabine) or BSC (12.4 months; 95% CI, 8.5-17.4; 11.5 months; 95% CI, 9.2-13.9; or 2.6 months; 95% CI, 1.9-3.1, respectively). The same trend was observed for 3-year OS rates: 27.0%, 17.0%, and 6.0% (P < .0001), respectively. Another comparative study 21 assessed the efficacy of LD-AraC relative to IC, HMAs, and BSC.
In that study, patients receiving IC appeared to have better OS outcomes compared to patients treated with LD-AraC (median OS:
12.4 vs. 9.6 months; 3-year OS: 27.0% vs. 12.0%; P ¼ .07), but LD-AraC significantly improved OS compared to BSC (median: 9.6 vs. 3.4 months, P ¼ .001). Medeiros found that the median OS associated with IC (18.9 months) was longer than OS associated with HMAs (6.6 months) or no treatment (1.5 months). Safety. The study of Ross et al 8 was the only one to report the safety of induction chemotherapies ( Table 5 ). The study examined 2 combinations of intensive induction chemotherapies; one combination was AraC and idarubicin (n ¼ 54), and the other was mitoxantrone and etoposide (n ¼ 8). It was reported that, across the 2 regimens, 39% of the patients developed bacteremia, whereas 17.8% developed bacterial pneumonia, and 14.5% developed fungal pneumonia. All patients developed grade 4 neutropenia and thrombocytopenia.
Discussion
Recap
The objectives of this SLR were to collect recent real-world effectiveness and safety outcomes associated with different treatment regimens for AML in the elderly population. Although more than 1800 unique citations were identified, only 14 articles examined either the effectiveness or safety of a specific intervention, illustrating the limited clinical evidence specifically for elderly patients with AML. Although one RCT was included in this review, the overall goal was to collect real-world information, and as such, most of the data included in this analysis emerged from observational studies. Results from comparative observational studies showed that IC was generally associated with longer median OS compared to other regimens, such as LD-AraC and BSC, among elderly AML patients. Most articles reported outcomes for azacitidine and high intensity chemotherapy; both are options that are referenced in clinical practice guidelines. Azacitidine is recommended for patients who are not candidates for intensive induction therapy (eg, patients with poor performance status and/or multiple comorbidities)
Azacitidine in Comparative Observational Studies and RCT
Findings from both comparative observational studies and an RCT suggested that azacitidine was associated with better survival compared to CCRs that included IC as well as LD-AraC and BSC. In the RCT, azacitidine significantly improved OS relative to CCRs (including BSC, LD-AraC, and IC) in a subgroup of poor-risk patients aged 65 years with newly diagnosed AML (median OS 6.4 vs. 3.2 months, respectively, P ¼ .019). 17, 18 Although a statistically significant result was not achieved for the overall AML population with intermediate-to poor-risk cytogenetics, the authors did note a clinically meaningful OS difference of 3.9 months in favor of azacitidine compared to conventional care (median OS, 10.4 vs. 6.4 months, respectively). 18 These results are encouraging, as elderly patients with poor-risk cytogenetics are usually not eligible for standard IC, and often receive only palliative treatment; median OS for this subset of patients is typically only 2 to 3 months. 24 In a comparative, retrospective study comparing azacitidine with different CCRs, AML patients with poor prognoses had higher median OS with azacitidine relative to LD-AraC (2-year OS rate, 37.0% vs. 5.0%, respectively); however, OS was similar among those treated with azacitidine and IC. 16 Another comparative observational study reported significantly higher 1-year OS rates in patients not suited for IC who were treated with azacitidine, relative to those not treated with azacitidine. 15 Together, these comparative studies demonstrate that azacitidine may be an important treatment option for poor-risk, difficult-to-treat AML patients.
Azacitidine in Noncomparative Observational Studies
Noncomparative studies examining azacitidine alone also were identified. These included de la Fuente et al, 12 an observational study examining azacitidine in AML patients aged 70 years and older. This study reported median OS statistics consistent with the RCT conducted by Dombret et al 18 and suggests that azacitidine is safe and effective in real-world, elderly AML patients. An open label, single arm, phase 2 study investigated azacitidine in combination with pracinostat, a histone deacetylase inhibitor, in patients aged 65 years with previously untreated AML who were unsuited for IC, and showed promising results for this combination regimen. 14 CR was achieved in 41.0% of patients and 60% were still alive after 1 year. These results compare favorably to the international, phase 3 RCT reported by Dombret et al 18 that noted a CR rate of only 19.5% and 1-year OS rates of 46.5% among patients treated with azacitidine alone. The only higher CR rates (50%e56%) were reported by studies that looked at physically fit, elderly patients receiving induction IC.
8,15
Outside the SLR: Azacitidine Versus Decitabine
None of the articles identified in the current SLR looked specifically at decitabine, another HMA that is currently available. To examine comparability to azacitidine, we decided to look outside of the scope of the SLR at recent studies that examined decitabine monotherapy in previously untreated elderly AML patients. He et al 25 published a meta-analysis of 9 studies that reported pooled estimates with 95% CIs. OS was 8.09 months (95% CI, 5.77-10.41 months), CR was 27% (95% CI, 19%e36%), and ORR was 37% (95% CI, 28%e47%). Mayer et al 26 
published results of an RCT
showing that decitabine is an effective and well-tolerated therapeutic alternative compared to treatment choice of either AraC or supportive care in newly diagnosed elderly patients with AML. Furthermore, subgroup analyses demonstrated favorable response rates for decitabine for all subgroups investigated, including patients 75 years (odds ratio 5.94, P ¼ .0006). The reported median OS for decitabine was lower compared to estimates reported for azacitidine; however, the reported CR and ORR were higher for decitabine relative to azacitidine. 26 
Other Treatment Regimens
Four real-world observational studies were identified that compared treatment modalities other than azacitidine, ie, various treatment classes including IC, HMAs, LD-AraC, and/or BSC. These studies generally enrolled elderly AML patients across all cytogenetic risk categories, and most did not appear to adjust for differences in baseline characteristics; therefore, results of these should be interpreted with caution. Most of the identified studies noted significant trends for improved survival with IC compared to HMAs, LD-AraC, BSC, or no treatment. [20] [21] [22] [23] Notably, Heiblig et al 21 found that LD-AraC in AML patients aged 70 years and older resulted in significantly improved survival relative to BSC, although their analysis appears to be unadjusted. A retrospective analysis of AML patients aged 66 years and older using the SEERMedicare database found significant survival benefits in separate analyses comparing HMAs to no treatment and IC to no treatment. 23 The authors employed multivariate models that adjusted for differences in patient characteristics and poor performance indicators across treatment groups. A substantial proportion of elderly AML patients do not receive any active therapy for their disease.
Findings from these studies suggest that age alone should not preclude the use of guideline-recommended therapies. Rather, the type of therapy (eg, intensive vs. HMAs) in elderly AML populations should be based on biological risk factors and physical fitness, which is in alignment with the NCCN recommendations. Indeed, Ross et al, 8 one of the noncomparative studies identified, showed that either favorable or intermediate cytogenetics or primary AML was prognostic of response in elderly AML patients treated with IC. This was the only study reporting safety outcomes in elderly AML patients treated with IC. 8 All patients in this study developed grade 4 neutropenia and thrombocytopenia, highlighting some of the challenges of administering IC regimens in an elderly population.
Outside the SLR: Other Treatments
Several other studies that were outside of the scope of the current SLR seemed to warrant some discussion. In 2011, Gunnar Juliusson published an update from the Swedish Acute Leukemia Registry. 27 This article was excluded from the SLR for reasons of geography and publication date. However, this study is important because the Swedish Acute Leukemia Registry contains data on 98% of all patients diagnosed since 1997, and was a large population-based source of real-world data comparing outcomes among elderly AML patients receiving IC versus BSC. This study found that early death rates were always lower with intensive treatment compared to palliative treatment; thus, most patients up to 75 years old in Sweden are given intensive induction treatment with acceptable complete remission rates. These results are similar to other studies of IC versus BSC that were part of this review. The author concluded that it is not acceptable to select untreated patients up to 80 years for palliation by considering them unfit for intensive treatment solely because of their age. 27 Other articles that were not identified as part of the SLR looked at clofarabine plus LD-AraC (CLDA) and gemtuzumab ozogamicin (GO). An observational study by Takahashi et al 28 examined CLDA versus intensive induction chemotherapy with idarubicin and highdose AraC (IA) as front-line therapy for elderly AML patients. No statistically significant differences in OS or response were detected between the 2 induction regimens. Significantly fewer toxicities of grade 3 or higher were noted with CLDA than with IA (46.3% vs. 62.1%, respectively; P ¼ .03). Additionally, when patients who underwent stem cell transplantation were removed from the group of responders, the median response duration was significantly longer with CLDA than with IA (15.9 months vs. 7.0 months, respectively; P ¼ .033). 28 Another study that was not included in this SLR was an RCT (NCT00091234) enrolling 237 elderly AML patients unfit for IC to receive either LD-GO or BSC. Amadori et al 29 reported OS of 4.9 months versus 3.6 months and a 1-year OS rate of 24.3% versus 9.7% for GO versus BSC, respectively. Consistent across most subgroups, this OS benefit was noted as particularly apparent in women and in patients with high CD33 expression status, or with a favorable/intermediate cytogenetic risk profile. Findings suggest that single-agent GO could represent a new option for this patient group. 29 
Study Size
All studies in this review had a sample size of at least 50 patients to ensure that only studies reporting robust treatmentrelated outcome evidence were included. In fact, approximately two thirds of the studies we identified enrolled 100 or more elderly AML patients. With regards to RCTs and observational comparative studies, an adequate sample size is important to ensure that the studies have acceptable levels of statistical power to detect significant differences between treatment regimens or classes, while reducing the likelihood that the differences observed are solely the result of chance. Indeed, one of the most robust studies included in this review was the international phase 3 clinical trial that examined azacitidine and enrolled close to 500 patients. 18 
Advantages of Observational Studies
Several comparative studies included in this review were realworld observational studies. While observational studies, by design, are considered inferior to RCTs, the evidence generated can often be useful and even complementary to the evidence achieved from clinical trials. One of the advantages of real-world observational studies is the opportunity to examine therapeutic strategies in actual practice settings, which are often subject to less controlled environments, and are also potentially more generalizable to a broader range of clinical settings. For example, the azacitidine evidence from the observational studies by Caroline et al 15 and
Michallet et al 16 serves to confirm some of the results reported in the RCT by Dombret et al. 18 Together, the evidence across these studies affirms the importance of azacitidine as an option in elderly unfit patients with AML.
Limitations
This SLR was subject to several limitations. First, the objective was to identify studies of elderly patients with AML. Much of the published literature included studies of AML mixed within a broader population of patients with other hematologic malignances. These "mixed" study types were not included in the review, as it was difficult to parse out the findings specific to AML from those specific to other types of hematologic disorders. Additionally, there was not a consistent definition of "elderly" among the studies appearing in the literature. It was usually defined according to 1 of 3 age cutoffs: age 60, 65, or 70 years old. The NCCN clinical practice guidelines for AML use a cutoff of 60 years old to define elderly patients. To be consistent with practice guidelines and to maximize the number of studies included in the review, this SLR also considered any patient aged 60 years old as elderly. Important patient characteristics, including age and cytogenetic risk score, differed among patients receiving IC versus those receiving lower-intensity therapy; this made it difficult to assess the clinical effectiveness of these 2 types of therapy classes across studies. Overall, clinical evidence for elderly patients with AML is limited; further research is needed to better understand outcomes to appropriately inform treatment decisions in these patients. Among the identified studies, treatment courses ranged from RIC HSCT to combination chemotherapy to monotherapy. The majority of studies assessed the effectiveness of azacitidine or other highintensity chemotherapeutic regimens. On the basis of the data reported by both an RCT and observational studies, azacitidine was associated with better efficacy and effectiveness outcomes when compared to other treatments, including LD-AraC and BSC, in elderly AML patients with poor-risk cytogenetics. While high rates of AEs such as neutropenia in studies examining IC demonstrate some of the challenges in treating elderly patients with AML, many studies indicate that age alone should not disqualify a patient from receiving intensive induction therapy if they are physically fit or have favorable cytogenetics. Although only a few studies report data on progression-free or disease-free survival, the high rates of AML disease progression associated with IC indicate a need for improved postremission options after intensive induction chemotherapy.
